This discrepancy in findings may be attributed to several factors, including differences in patient populations, treatment protocols, and P-gp detection methods, particularly variations in immunohistochemical antibodies and scoring methodologies employed to assess P-gp expression.[22] Furthermore, the impact of P-gp on prognosis may be influenced by the specific subtype of osteosarcoma, the presence of other resistance mechanisms, and the tumor microenvironment.[24–26]. This evidence concerns the gene PGP and neoplasm.